- Home
- UGRO vs REVB Comparison
UGRO vs REVB Comparison
Compare UGRO & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- REVB
- Stock Information
- Founded
- UGRO 2014
- REVB 2020
- Country
- UGRO United States
- REVB United States
- Employees
- UGRO N/A
- REVB N/A
- Industry
- UGRO Industrial Specialties
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- REVB Health Care
- Exchange
- UGRO Nasdaq
- REVB Nasdaq
- Market Cap
- UGRO 3.8M
- REVB 3.8M
- IPO Year
- UGRO N/A
- REVB N/A
- Fundamental
- Price
- UGRO $0.40
- REVB $2.44
- Analyst Decision
- UGRO Strong Buy
- REVB
- Analyst Count
- UGRO 1
- REVB 0
- Target Price
- UGRO $3.00
- REVB N/A
- AVG Volume (30 Days)
- UGRO 488.3K
- REVB 303.2K
- Earning Date
- UGRO 08-12-2025
- REVB 08-12-2025
- Dividend Yield
- UGRO N/A
- REVB N/A
- EPS Growth
- UGRO N/A
- REVB N/A
- EPS
- UGRO N/A
- REVB N/A
- Revenue
- UGRO $59,985,138.00
- REVB N/A
- Revenue This Year
- UGRO N/A
- REVB N/A
- Revenue Next Year
- UGRO $31.25
- REVB N/A
- P/E Ratio
- UGRO N/A
- REVB N/A
- Revenue Growth
- UGRO N/A
- REVB N/A
- 52 Week Low
- UGRO $0.26
- REVB $2.11
- 52 Week High
- UGRO $1.92
- REVB $168.00
- Technical
- Relative Strength Index (RSI)
- UGRO 50.89
- REVB 36.87
- Support Level
- UGRO $0.42
- REVB $2.31
- Resistance Level
- UGRO $0.55
- REVB $2.88
- Average True Range (ATR)
- UGRO 0.07
- REVB 0.24
- MACD
- UGRO 0.00
- REVB 0.01
- Stochastic Oscillator
- UGRO 37.73
- REVB 14.29
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).